Brandon Capital

Brandon Capital is a distinguished life sciences venture capital firm headquartered in Melbourne, Australia, with a global presence extending across New Zealand, the United Kingdom, and the United States. Established in 2007 by co-founders Chris Nave and Stephen Thompson, the firm is dedicated to identifying, funding, and nurturing groundbreaking biomedical technologies with the potential to significantly improve patient lives worldwide. Brandon Capital's core mission is to transform promising medical research breakthroughs into commercial medical therapies and internationally competitive companies.

The firm plays a crucial role in advancing the life sciences ecosystem by investing in early-stage and high-growth medical science companies. They serve a diverse range of entities, from Australian and New Zealand startups to scale-ups and established international businesses in the biotech and healthcare sectors. Brandon Capital provides not only capital but also strategic guidance, management expertise, and access to an extensive network, ensuring portfolio companies are supported from proof-of-concept through to commercialisation.

What sets Brandon Capital apart is its deep domain expertise and its unique collaboration model through Brandon BioCatalyst, a consortium of over 50 leading Australian and New Zealand medical research institutes and hospitals. This proprietary deal flow strengthens their ability to source and create high-potential biomedical innovations from their inception. The firm's investment strategy focuses on early-stage innovations with strong scientific and commercial potential, aiming to build a sustainable biotech industry that delivers both financial returns and improved patient outcomes.

Key achievements include raising over AU$1.25 billion across six successive funds, making it Australasia's largest life science investor. Their latest, Brandon BioCatalyst Fund Six (BB6), successfully closed at AU$439 million. To date, Brandon Capital has made more than 60 investments in new therapeutic, medical device, and healthtech companies, with an active portfolio of over 30 companies, many of which are in clinical trials or nearing market entry. They have a proven track record of successful exits and have been selected by the Australian Government to manage the Biomedical Translation Fund, highlighting their expertise and impact.

Leadership at Brandon Capital includes Founding Partner & Managing Director Chris Nave, who also serves as CEO of Brandon BioCatalyst, and Founding Partner & Managing Director Stephen Thompson. Other key partners include Melissa McBurnie, Partner & Head of Impact, Chris Smith, Partner, and Jonathan Tobin, Partner and head of the London office. This leadership team brings a wealth of scientific, commercial, and operational experience, driving Brandon Capital's collaborative and transparent culture focused on converting high-quality science into important medicines.